Semaglutide found to be effective against type 2 diabetes

May 21, 2018

(HealthDay)—Semaglutide is safe and effective for the treatment of type 2 diabetes, according to a review published online May 13 in Diabetes, Obesity and Metabolism.

Panagiotis Andreadis, M.D., from the Aristotle University of Thessaloniki in Greece, and colleagues conducted a systematic literature review to identify comparing semaglutide with or other antidiabetic agents. The primary outcome was measured change in HbA1c from baseline.

Six placebo-controlled and seven active-controlled studies were identified. The researchers found that subcutaneous semaglutide (0.5 and 1 mg) reduced HbA1c by 1.01 percent (95 percent confidence interval [CI], 0.56 to 1.47) and 1.38 percent (95 percent CI, 1.05 to 1.70), respectively, compared to placebo. Compared to other antidiabetic agents (sitagliptin, exenatide, liraglutide, dulaglutide, and insulin glargine), both doses of semaglutide demonstrated superior glycemic efficacy. There was a beneficial effect on (mean difference versus placebo −4.11 kg; 95 percent CI, −4.85 to −3.37 for semaglutide 1 mg) and with semaglutide. There was increased incidence of nausea, vomiting, and diarrhea with semaglutide. Compared to placebo, the odds ratio for diabetic retinopathy was 1.32 (95 percent CI, 0.98 to 1.77).

"Semaglutide is a potent once-weekly glucagon-like peptide 1 receptor agonist, reducing significantly HbA1c, body weight, and systolic blood pressure. However, it is associated with increased incidence of gastrointestinal adverse events," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Novo Nordisk, the manufacturer of semaglutide.

Explore further: New diabetes drug may help people with obesity lose weight

More information: Abstract/Full Text (subscription or payment may be required)

Related Stories

New diabetes drug may help people with obesity lose weight

March 18, 2018
A compound that mimics a naturally occurring hormone that regulates appetite may help people who have obesity but not diabetes to lose weight, a new study suggests. The research will be presented Sunday, March 18, at ENDO ...

Rate of CVD mortality, MI, stroke down for patients on semaglutide

September 17, 2016
(HealthDay)—Semaglutide is noninferior to placebo for patients with type 2 diabetes at high cardiovascular risk, according to a study published online Sept. 16 in the New England Journal of Medicine. The research was published ...

Diabetes pill might replace injection to control blood sugar

October 17, 2017
(HealthDay)— An injectable class of diabetes medication—called glucagon-like peptide-1 or GLP-1—might one day be available in pill form, research suggests.

Trial shows drug can dramatically reduce weight of people with obesity

October 23, 2017
A drug that targets the appetite control system in the brain could bring about significant weight loss in people with clinical obesity, according to new research.

Liraglutide not tied to higher risk of cardiovascular events

October 13, 2017
(HealthDay)—Liraglutide treatment for weight management is not associated with increased risk of cardiovascular events, according to a study published online Sept. 26 in Diabetes, Obesity and Metabolism.

Review compares outcomes, safety for once-weekly GLP-1RAs

December 8, 2015
(HealthDay)—Cardiometabolic outcomes and safety vary among different once-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) treatments, according to a review published online Dec. 8 in the Annals of Internal Medicine.

Recommended for you

Healthy fat cells uncouple obesity from diabetes

August 14, 2018
About 422 million people around the world, including more than 30 million Americans, have diabetes. Approximately ninety percent of them have type 2 diabetes. People with this condition cannot effectively use insulin, a hormone ...

'Alarming' diabetes epidemic in Guatemala tied to aging, not obesity

August 14, 2018
The diabetes epidemic in Guatemala is worse than previously thought: more than 25 percent of its indigenous people, who make up 60 percent of the population, suffer from type 2 diabetes or pre-diabetes, suggests a new study ...

Gut reaction linked to type 1 diabetes

August 13, 2018
Understanding the link between diabetes and the gut could lead to the development of new therapies to delay the onset of type 1 diabetes, according to University of Queensland researchers.

Early age of type 1 diabetes diagnosis linked to shorter life expectancy, compared to later diagnosis

August 10, 2018
Life-expectancy for individuals with younger-onset disease is on average 16 years shorter compared to people without diabetes, and 10 years shorter for those diagnosed at an older age

Red blood cells cause cardiovascular injury in type 2 diabetes

August 7, 2018
Harmful effects of substances secreted from red blood cells could explain the increased risk of cardiovascular diseases in patients with type 2 diabetes, the results of two new studies conducted at Karolinska Institutet in ...

Diabetes in bay area Chinese population linked to fat fibrosis

August 6, 2018
A new UC San Francisco study has discovered a key biological difference in how people of European and Chinese descent put on weight—a finding that could help explain why Asians often develop type 2 diabetes at a much lower ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.